These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36602798)

  • 1. Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma.
    Brazel D; Kumar P; Doan H; Pan T; Shen W; Gao L; Moyers JT
    JAMA Netw Open; 2023 Jan; 6(1):e2249674. PubMed ID: 36602798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
    Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
    Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.
    Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R
    Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
    Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
    Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.
    Harms KL; Lazo de la Vega L; Hovelson DH; Rahrig S; Cani AK; Liu CJ; Fullen DR; Wang M; Andea AA; Bichakjian CK; Johnson TM; Tomlins SA; Harms PW
    JAMA Dermatol; 2017 Jun; 153(6):505-512. PubMed ID: 28403382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
    Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
    JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PI3K signaling in Merkel cell carcinoma.
    Nardi V; Song Y; Santamaria-Barria JA; Cosper AK; Lam Q; Faber AC; Boland GM; Yeap BY; Bergethon K; Scialabba VL; Tsao H; Settleman J; Ryan DP; Borger DR; Bhan AK; Hoang MP; Iafrate AJ; Cusack JC; Engelman JA; Dias-Santagata D
    Clin Cancer Res; 2012 Mar; 18(5):1227-36. PubMed ID: 22261808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
    Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
    Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
    Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
    Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
    Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
    Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.
    Wong SQ; Waldeck K; Vergara IA; Schröder J; Madore J; Wilmott JS; Colebatch AJ; De Paoli-Iseppi R; Li J; Lupat R; Semple T; Arnau GM; Fellowes A; Leonard JH; Hruby G; Mann GJ; Thompson JF; Cullinane C; Johnston M; Shackleton M; Sandhu S; Bowtell DD; Johnstone RW; Fox SB; McArthur GA; Papenfuss AT; Scolyer RA; Gill AJ; Hicks RJ; Tothill RW
    Cancer Res; 2015 Dec; 75(24):5228-34. PubMed ID: 26627015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
    Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
    JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
    Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
    JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from squamous dysplastic precursors.
    Harms PW; Verhaegen ME; Hu K; Hrycaj SM; Chan MP; Liu CJ; Grachtchouk M; Patel RM; Udager AM; Dlugosz AA
    Mod Pathol; 2022 Apr; 35(4):506-514. PubMed ID: 34593967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.
    Attalla K; DiNatale RG; Rappold PM; Fong CJ; Sanchez-Vega F; Silagy AW; Weng S; Coleman J; Lee CH; Carlo MI; Durack JC; Solomon SB; Reuter VE; Russo P; Chan TA; Motzer RJ; Schultz ND; Reznik E; Voss MH; Hakimi AA
    Clin Cancer Res; 2021 Oct; 27(20):5595-5606. PubMed ID: 34261695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal.
    DeCoste RC; Carter MD; Pasternak S; Fleming KE; Gaston D; Legge A; Ly TY; Walsh NM
    Hum Pathol; 2021 Nov; 117():31-41. PubMed ID: 34391748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.